Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pilar de la Puente
Observed names:
De La Puente, Pilar,
P de la Puente,
P. de la Puente,
Pilar De La Puente,
de la Puente, Pilar
Institutions:
University of South Dakota,
Sanford USD Medical Center,
Sanford Research
Observed institutions:
South Dakota State University,
University of South Dakota,
Washington University in St. Louis,
Sanford USD Medical Center,
San Francisco Foundation,
Sanford Research
show all 6
ORCID:
0000-0001-5953-1197
Observed ORCID:
0000-0001-5953-1197
OpenAlex ID:
A5016763648
Works
83
Awards
5
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
2015
·
Barbara Muz
, Pilar de la Puente
, et al.
·
Hypoxia
·
2,180
PDF
Cell culture in autologous fibrin scaffolds for applications in tissue engineering
2014
·
Pilar de la Puente
, Dolores Ludeña
·
Experimental Cell Research
·
149
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma
2015
·
Pilar de la Puente
, Barbara Muz
, et al.
·
Biomaterials
·
143
Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy
2015
·
Micah John Luderer
, Pilar de la Puente
, et al.
·
Pharmaceutical Research
·
130
Cell Trafficking of Endothelial Progenitor Cells in Tumor Progression
2013
·
Pilar de la Puente
, Barbara Muz
, et al.
·
Clinical Cancer Research
·
113
Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models
2020
·
Somshuvra Bhattacharya
, Kristin Calar
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
110
PDF
Hypoxia promotes stem cell-like phenotype in multiple myeloma cells
2014
·
B Muz
, P de la Puente
, et al.
·
Blood Cancer Journal
·
83
PDF
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
2020
·
Cinzia Federico
, Kinan Alhallak
, et al.
·
Nature Communications
·
81
PDF
Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer
2022
·
Megan M. Jorgensen
, Pilar de la Puente
·
Biomolecules
·
80
PDF
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
2017
·
Pilar de la Puente
, Micah J. Luderer
, et al.
·
Journal of Controlled Release
·
69
PDF
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors
2017
·
Pilar de la Puente
, Nicole Fettig
, et al.
·
Journal of Pharmaceutical Sciences
·
65
The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies
2014
·
Barbara Muz
, Pilar de la Puente
, et al.
·
Molecular Cancer Research
·
62
Molecularly Targeted Therapies in Multiple Myeloma
2014
·
Pilar de la Puente
, Barbara Muz
, et al.
·
Leukemia Research and Treatment
·
60
Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma
2017
·
Pilar de la Puente
, Abdel Kareem Azab
·
European Journal Of Haematology
·
57
PDF
Autologous fibrin scaffolds cultured dermal fibroblasts and enriched with encapsulated bFGF for tissue engineering
2011
·
Pilar de la Puente
, Dolores Ludeña
, et al.
·
Journal of Biomedical Materials Research Part A
·
47
Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy
2019
·
Micah John Luderer
, Barbara Muz
, et al.
·
Pharmaceutical Research
·
45
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance
2014
·
Feda Azab
, Shireen Vali
, et al.
·
British Journal of Haematology
·
45
Bioengineering the Oxygen-Deprived Tumor Microenvironment Within a Three-Dimensional Platform for Studying Tumor-Immune Interactions
2020
·
Somshuvra Bhattacharya
, Kristin Calar
, et al.
·
Frontiers in Bioengineering and Biotechnology
·
41
PDF
Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
2015
·
Barbara Muz
, Feda Azab
, et al.
·
BioMed Research International
·
37
PDF
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
2017
·
Barbara Muz
, Feda Azab
, et al.
·
Translational Oncology
·
36
PDF
Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance
2017
·
Barbara Muz
, Hubert D. Kusdono
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
36
Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid
2020
·
Mariah M. Hoffman
, Jessica S. Zylla
, et al.
·
Cancers
·
35
PDF
Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia
2014
·
Barbara Muz
, Pilar de la Puente
, et al.
·
Molecular Cancer Research
·
34
A CD 138‐independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma
2016
·
Barbara Muz
, Pilar de la Puente
, et al.
·
British Journal of Haematology
·
33
The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma
2017
·
Nicholas Burwick
, Michael Y. Zhang
, et al.
·
Leukemia Research
·
32
Show more works
View as search
Works count:
83
Citation count:
4,169
H-index:
26
I10-index:
43
Year
Topic
Type
